Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: a call for a dose update

OBJECTIVES: Optimal dosage regimens of colistin for the treatment of urinary tract infections (UTI) are unknown. Colistimethate sodium (CMS), the inactive prodrug of colistin, is mainly excreted in urine and converts to colistin after filtration by glomeruli, suggesting that concentrations of colist...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Infect
Egile Nagusiak: Sorlí, Luisa, Luque, Sonia, Li, Jian, Campillo, Núria, Danés, Marc, Montero, Milagro, Segura, Concha, Grau, Santiago, Horcajada, Juan Pablo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7265153/
https://ncbi.nlm.nih.gov/pubmed/31265867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jinf.2019.06.011
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak